Biogen
BIIB
1,025 hedge funds and large institutions have $53.8B invested in Biogen in 2016 Q4 according to their latest regulatory filings, with 137 funds opening new positions, 364 increasing their positions, 401 reducing their positions, and 107 closing their positions.
87.15% more ownership
Funds ownership: 0% → 87.15% (+87%)
28% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 107
1% more funds holding
Funds holding: 1,012 → 1,025 (+13)
9% less repeat investments, than reductions
Existing positions increased: 364 | Existing positions reduced: 401
9% less capital invested
Capital invested by funds: $59.3B → $53.8B (-$5.52B)
13% less call options, than puts
Call options by funds: $1.52B | Put options by funds: $1.74B
28% less funds holding in top 10
Funds holding in top 10: 57 → 41 (-16)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$387M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$329M |
| 3 |
Two Sigma Investments
New York
|
+$159M |
| 4 |
Renaissance Technologies
New York
|
+$139M |
| 5 |
Two Sigma Advisers
New York
|
+$132M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$733M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$450M |
| 3 |
SIG
Senator Investment Group
New York
|
-$142M |
| 4 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$142M |
| 5 |
HM
HealthCor Management
New York
|
-$117M |
BIIB Hedge Fund Activity: Q4 2016 in Review
1,025 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2016, worth a combined $53.8B — down 9.3% from $59.3B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new BIIB positions and 107 closed out — a net gain of 30 holders — while 364 added to existing stakes and 401 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $387M. The largest seller was Jennison Associates, cutting an estimated $733M.
- 1,025 institutional investors held Biogen (BIIB) as of Q4 2016, up from 1,012 in Q3 2016.
- Funds reported $53.8B of Biogen stock for Q4 2016, down 9.3% quarter-over-quarter.
- 137 funds opened new Biogen positions in Q4 2016 and 107 closed out, a net change of +30 holders.
- The largest Biogen buyer in Q4 2016 was Wellington Management Group, an estimated $387M added.
- The largest Biogen seller in Q4 2016 was Jennison Associates, an estimated $733M sold.
Based on aggregated 13F filings for Q4 2016.